Alembic Pharmaceuticals has received U.S. Food and Drug Administration final approval for its abbreviated new drug application for Carbidopa, Levodopa and Entacapone Tablets in different strengths. The combination drug is indicated for the treatment of Parkinson’s. The approved ANDA is therapeutically equivalent to reference listed drug Stalevo Tablets of Orion Corporation, Alembic said on Friday announcing the U.S. FDA approval. The company’s shares closed 1.32% lower at ₹799.05 apiece on the BSE. Published – February 06, 2026 10:07 pm IST Share this: Click to share on WhatsApp (Opens in new window) WhatsApp Click to share on Facebook (Opens in new window) Facebook Click to share on Threads (Opens in new window) Threads Click to share on X (Opens in new window) X Click to share on Telegram (Opens in new window) Telegram Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Pinterest (Opens in new window) Pinterest Click to email a link to a friend (Opens in new window) Email More Click to print (Opens in new window) Print Click to share on Reddit (Opens in new window) Reddit Click to share on Tumblr (Opens in new window) Tumblr Click to share on Pocket (Opens in new window) Pocket Click to share on Mastodon (Opens in new window) Mastodon Click to share on Nextdoor (Opens in new window) Nextdoor Click to share on Bluesky (Opens in new window) Bluesky Like this:Like Loading... Post navigation Law and order: Lurking danger in unscheduled halts of police escort vehicles with prisoners at wayside hotels Differently abled voters need to queue up for SIR hearings in West Bengal despite ECI directives